Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
Fanti P. A., Vaccari S., Ghetti E., Misciali C.
Sezione di Clinica Dermatologica Dipartimento di Medicina Clinica Specialistica e Sperimentale Università degli Studi di Bologna, Bologna
Background. Actinic keratosis (AK) are epidermal dysplasia or squamous cell carcinomas in situ of sun-damaged skin. The risk of progression into invasive squamous cell carcinoma has a range of 0,125% to 16% per year. Imiquimod is a new topical immune response modifier useful in treating UV induced skin lesion.
Methods. Thirty patients affected by recurrent AK of the face have been treated with Imiquimod 5% cream 3 times a week for 4 weeks. The product was left in site for 8 hours and then washed off with soap. A topic irritative skin reaction in the application area was observed. Most patients showed only an erythematous reaction, while erythematovesicular lesions were observed in 8 patients. Two patients had a crusting phenomenon. No patients suspended the treatment.
Results. All the AK neoplasms cleared after therapy with Imiquimod cream 5% for 4 weeks, except for 3 patients who showed persistence of 1 or 2 hyperkeratotic AK.
Conclusions. This study demonstrates that topical Imiquimod is a good strategy for the therapy of actinic keratosis and is probably helpful in preventing the progression to invasive squamous cell carcinoma of sun-damaged skin.